Physician profile
Stephen Galston
NPI 1508939471
$1,020.63
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $795 · 2020: $202 · 2021: $22.87.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $168.70 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $137.41 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $114.26 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $92.16 | 2019-2020 | |
| Tris Pharma INC | $63.16 | 2019 | |
| Lundbeck LLC | $60.64 | 2019-2020 | |
| Neos Therapeutics, LP | $59.99 | 2019 | |
| Allergan, INC. | $56.78 | 2019 | |
| Shire North American Group INC | $45.34 | 2019 | |
| Ironshore Pharmaceuticals INC. | $43.40 | 2019 | |
| Sunovion Pharmaceuticals INC. | $42.16 | 2019 | |
| Vertical Pharmaceuticals, LLC | $31.67 | 2019 | |
| Owp Pharmaceuticals, INC. | $27.12 | 2019 | |
| Adlon Therapeutics L.P. | $25.58 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $22.87 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $15.94 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $13.45 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Galston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.